Abstract
Background Patients with advanced lung disease who present with suspicious pulmonary nodules (SPNs) undergoing transthoracic needle aspiration pose a diagnostic challenge given risk for complications. Virtual bronchoscopic navigation (VBN) is an alternative means to biopsy patients.
Study Design The study was a retrospective chart review of all patients who underwent VBN with the Archimedes platform. Demographic information, radiographic evidence of parenchymal lung disease and pulmonary function testing were gathered. Peri-procedure complications and clinical data on biopsy results were gathered to assist in determining both adequate tissue sample (defined if adequate specimen was obtained as per pathology/cytology report) and diagnostic yield (defined as if after further testing/CT imaging from 1 year post-procedure the diagnosis did not change). Univariate analysis was performed to determine the impact of clinical factors on diagnostic yield.
Results Ninety-six patients with 110 nodules underwent VBN. Eight-eight patients (92%) had radiographic emphysema with 56% having moderate to severe. Fourteen patients (17%) had radiographic ILD. Adequate tissue sample at time of VBN was 93%. Overall diagnostic yield in 80 patients (excluding 16 patients who were initially benign/non-diagnostic that were lost to follow-up) was 72%. Overall complication rate was 7% with 1-pneumothorax (1%), 3-significant bleeding and 3-hospitalized for respiratory failure.
Conclusion In our cohort of patients the diagnostic yield and complication rate were comparable to other studies where there were fewer patients with advanced lung disease. This data suggests that VBN-guided bronchoscopic biopsy of SPNs is a viable diagnostic option with an acceptable safety profile.
Competing Interest Statement
S. Verga: Nuvaira G. Criner: - Grants received: NIH-NHLBI, PA-DOH, GSK, Boehringer-Ingelheim, Novartis, Astra Zeneca, Respironics, MedImmune, Novartis, Pearl, PneumRx, Pulmonx, Broncus, Spiration, Olympus, Fisher-Paykel Healthcare, Chiesi, Gilead, Pfizer, Corvus, Lilly, Regeneron, Genetech, Roche - Grants pending: NIH-NHLBI, Nuvaira, CSA Medical - Consultation: Amirall, Astra Zeneca, Nuvaira, GSK, CSA Medical, PneumRX, BTG, Mereo, Broncus, Pulmonx, GSK, EOLO, AERWAVE R. Marron, C. Veselis, C. Dass, and H. Zhao: none
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Temple University gave ethical approval for this work. The IRB Protocol ID # 26644.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- (SPNs)
- Suspicious Pulmonary Nodules
- (VBN)
- Virtual Bronchoscopic Navigation
- (ILD)
- Interstitial Lung Disease
- (TUH)
- Temple University Hospital
- (PFT)
- Pulmonary Function Testing
- (FEV1)
- Forced Expiratory volume in 1-second
- (FVC)
- Force Vital Capacity
- (DLCO)
- Diffusing Capacity for Carbon Monoxide
- (TLC)
- Total Lung Capacity
- (LDCT)
- Low Dose Computed Tomography
- (NLST)
- National Lung Screening Trial
- (VATS)
- Video-Assisted Thoracic Surgery
- (TTNA)
- Transthoracic Needle Aspiration
- (EBUS)
- Endobronchial Ultrasound
- (ENB)
- Electromagnetic Navigational Bronchoscopy
- (rEBUS)
- radial EBUS
- (BTPNA)
- Bronchoscopic Transparenchymal Nodule Access
- (PTX)
- Pneumothorax
- (FDG-PET)
- Fluorodeoxyglucose-Position Emission Tomography
- (TBBx)
- Transbronchial Biopsy
- (FNA)
- Fine Needle Aspiration
- (BAL)
- Bronchoalveolar Lavage
- (ROSE)
- Rapid On-site Cytopathological Examination
- (ICU)
- Intensive Care Unit
- (RUL)
- Right Upper Lobe
- (LUL)
- Left Upper Lobe
- (CPFE)
- Combine Pulmonary Fibrosis and Emphysema
- (OR)
- Odds Ratio